Results 211 to 220 of about 78,778 (305)

Carrier‐Free Berberine/Nitidine Chloride Self‐Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma

open access: yesAdvanced Science, Volume 13, Issue 62, 9 November 2026.
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv   +16 more
wiley   +1 more source

Intrasplenic Thymus Organogenesis from Injectable Tissue Fragments Restores Functional T‐Cell Immunity

open access: yesAdvanced Science, Volume 13, Issue 63, 12 November 2026.
Clinical intramuscular thymus transplantation yields only short‐lived efficacy and marginal therapeutic benefits. Benefiting from the spleen's intrinsic strengths—rapid vascular perfusion, abundant developmental factors, and resident progenitors—the intrasplenic thymic grafts achieve robust thymic regeneration and substantial T‐cell reconstitution ...
Shaocong Wang   +10 more
wiley   +1 more source

Chronic Active Epstein–Barr Virus (EBV) Disease with Haemophagocytic Lymphohistiocytosis and Abnormal T/NK Cells

open access: yes
eJHaem, Volume 7, Issue 6, December 2026.
Buthaina Al Maashari   +4 more
wiley   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

open access: yesAmerican Journal of Hematology, Volume 101, Issue 11, Page 2836-2852, November 2026.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas   +4 more
wiley   +1 more source

HCV-Specific T-Cell Recovery After a Year of SVR Following DAA Therapy. [PDF]

open access: yesJ Med Virol
Pozniak T   +9 more
europepmc   +1 more source

A Real‐World Study on the Use of Recombinant Human Thrombopoietin for Managing Thrombocytopenia Following Tandem Dual‐Target CAR‐T Cell Therapy in B‐Cell Malignancies

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Objective Given that CD19 chimeric antigen receptor T (CAR‐T) cell therapy frequently induces severe thrombocytopenia and recombinant human thrombopoietin (rhTPO)′s role in managing this CAR‐T‐associated cytopenia remains not well defined, we aimed to evaluate rhTPO's safety and efficacy for treating thrombocytopenia in B‐cell malignancy ...
Jiaqi Guo   +10 more
wiley   +1 more source

Impact of CD38 Deficiency on B Cell Development in CD19-Deficient Mice. [PDF]

open access: yesScand J Immunol
Abrego-Peredo A   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy